ANZCHOG Children’s Cancer Clinical Trials Repository

Study Title
Interfant21: International collaborative treatment protocol for infants under one year with KMT2A rearranged acute lymphoblastic leukemia or mixed phenotype acute leukemia
Protocol ID
Interfant21
Condition/s
B- precursor acute lymphoblastic leukemia (ALL)
B- cell mixed phenotype acute leukemia (MPAL)
Diagnosis Stage
Newly diagnosed
Location
NSW, QLD, VIC, WA, SA
Sponsor
Australian & New Zealand Children's Haematology/Oncology Group
Collaborators
Princess Maxima Center for Pediatric Oncology
Trial Status
Open
Sites
Perth Children's Hospital
Monash Children's Hospital
Queensland Children's Hospital
The Children's Hospital at Westmead
Women's and Children's Hospital
Study Type
Treatment
Phase
Phase 3
Age Eligibility
up to 1 Year
International registry ID's
NCT05327894
Back to Registry
Study Title Interfant21: International collaborative treatment protocol for infants under one year with KMT2A rearranged acute lymphoblastic leukemia or mixed phenotype acute leukemia
Protocol ID Interfant21
Disease (Sub Disease) B- precursor acute lymphoblastic leukemia (ALL)
B- cell mixed phenotype acute leukemia (MPAL)
Diagnosis Stage Newly diagnosed
Location NSW / QLD / VIC / WA / SA
Sponsor Australian & New Zealand Children's Haematology/Oncology Group
Collaborators Princess Maxima Center for Pediatric Oncology
Links https://clinicaltrials.gov/study/NCT05327894
Trial Status Open
Trial Open Date 30/04/2024
Sites Perth Children's Hospital/ Monash Children's Hospital/ Queensland Children's Hospital/ The Children's Hospital at Westmead/ Women's and Children's Hospital
Study Type Treatment
Phase Phase 3
Age Eligibility up to 1 Year
International registry ID's NCT05327894

Join our newsletter

"*" indicates required fields

This field is for validation purposes and should be left unchanged.

Email info@anzchog.org   |  

Level 6, TRF Building, Hudson Institute, 27-31 Wright St, Clayton VIC 3168